Login or Register
Cardio Debate > Courses > NEW ANTIANGINAL AGENTS – FOCUS ON RANOLAZINE
NEW ANTIANGINAL AGENTS – FOCUS ON RANOLAZINE

Disclaimer

This programme has received an educational grant from A. Menarini Farmaceutica Internazionale Srl [AMFI]. Any comments or opinions expressed by the authors are independent of any editorial input from AMFI and do not necessarily reflect the views of AMFI.

Scientific programme prepared by
The Cardiovascular and Cell Sciences Research Institute, St George’s University of London, London, UK.
Objectives

Managing chronic stable angina pectoris continues to represent a challenge to the practicing physician. Novel anti-angina agents have been incorporated to our therapeutic arsenal in recent years. Ranolazine is one of such agents with novel mechanisms of actions. This programme focuses on the indications, contraindications and practical use of this agent in clinical practice. General practitioners, hospital consultants and clinical-academics contribute their expert views and practical suggestions in this online educational programme.

Programme coordinator
Prof Juan Carlos Kaski

Professor of Cardiovascular Science, Cardiovascular and Cell Sciences Research Institute,St George’s, University of London, UK

Content
Cardio Notes
Brief summaries of specific topics related to the use of anti-angina agents and practical comments by experts
  1. Guidelines (ESC & NICE) for the pharmacological management of angina pectoris - What's new?
  2. Pharmacological treatment of stable angina - Conventional and novel anti-anginal agents
  3. Ranexa - Mode of action, dosing and side effects
  4. Ranolazine: indications, adverse reactions and contraindications
  5. Use of ranolazine in chronic stable angina patients and patients with type 2 diabetes mellitus - Summary of CARISA, MARISA & TERISA trials
  6. Concomitant use of ranolazine and conventional anti-anginal agents
Cardio Interviews
Face to face discussions on the management of angina pectoris and the use of ranolazine in clinical practice
  1. Management of angina and the role of Ranolazine in the context of the NICE guidelines
  2. Clinical cases where an indication for ranolazine may exist
  3. Antianginal agents: Beneficial effects of Ranolazine
  4. Antianginal agents: Prescribing in real life clinical practice
Expert opinions by
Dr Chris Arden
General Practitioner with special interest in Cardiology. Park Surgery, Chandlers Ford, Southampton.
Prof Juan Carlos Kaski

Professor of Cardiovascular Science, Cardiovascular and Cell Sciences Research Institute,St George’s, University of London, UK

Prof John Camm
Professor of Cardiology, Cardiovascular and Cell Sciences Research Institute, St George’s, University of London. Previously he was President of the British Cardiovascular Society and a Council member of the Royal College of Physicians.
Dr Rajan Sharma
Consultant Cardiologist St Georges Hospital, London, UK
Dr Ravi Patel
General Practitioner Morden Hall Medical Centre, London, UK.